Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company’s investigational RNA interference ...

The placebo-controlled study is aimed at assessing the safety and efficacy of zodasiran in adults and adolescents with HoFH.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company’s investigational RNA ...

The Paroxysmal Nocturnal Hemoglobinuria treatment market is experiencing significant expansion, driven by increasing disease awareness, rising preval ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mereo Biopharma Group Plc (MREO – Research Report), Amgen (AMGN – Research Rep ...

Arrowhead Pharmaceuticals, Inc. (ARWR) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions ...

ARO-C3 is an investigational RNA interference therapeutic designed to reduce liver production of complement component 3 as a potential therapy for various complement-mediated diseases.

The firm is hoping to show that the RNAi drug can treat HoFH by reducing production of ANGPTL3, which regulates lipid and lipoprotein metabolism.

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, ...